Lexaria Bioscience Corp. (NASDAQ: LEXX) (CSE: LXX) Announces Milestone in Antiviral Delivery Platform Testing
Drug delivery platform developer Lexaria Bioscience has been testing its patented technology in conjunction with antivirals Remdesivir and Ebastine during the past year to determine the potential for enhancing their effectiveness against the COVID-19 virus Early-stage testing has determined Lexaria’s technology — DehydraTECH — did not inhibit Remdesivir and Ebastine in their use against the virus DehydraTECH is a technology that helps drugs gain better bioavailability through effective introduction into patients’ bloodstreams The DehydraTECH platform has also shown great potential in enhancing hypertension medication and additional trials are ongoing Pharmaceutical use and bioavailability innovator Lexaria Bioscience (NASDAQ: LEXX) (CSE: LXX)…